You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
三生制药(01530.HK)附属与瑞士生物制药商合作开发新型肿瘤免疫多特异性抗体
阿思达克 12-12 18:06

三生制药(01530.HK)公布,集团附属三生国健与瑞士苏黎世区的生物制药公司Numab Therapeutics合作开发一系列肿瘤免疫新型多特异性抗体。三生国健将基於Numab的技术平台开发和商业化一系列用於癌症治疗的新型多特异性抗体。

根据协议,三生国健有权在Numab研发平台的三个多特异性抗体项目中选取多达五种抗体分子,并拥有所选抗体分子在大中华区(包括中国大陆、香港、澳门和台湾)的开发及商业化专有许可权,其他区域的独家商业权利由Numab保留。同时,三生国健已经在Numab的B轮融资中投资了1,500万瑞士法郎(约1,520万美元)。

集团指,Numab的独家MATCHTM技术已经造就了一个强大的多特异性抗体候选药物管线,其主导项目ND021是一种抗-4-1BB/PD-L1/HSA三特异性抗体,将在明年进入临床试验。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account